Skip to content
value.today

Neuraltus Pharmaceuticals, Inc.

🇺🇸 Menlo Park, California, USAPharmaceuticalsFounded 2004

Formerly Taiji Biomedical, Inc.

Total raised
$31 M
3 rounds on record
Latest round
$15 M
May 2016
First round on record
Mar 2009
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Neuraltus Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2016$15 MNo. 3$10 to $50 million

Neuraltus Pharmaceuticals, Inc.: Raise no. 3, May 2016

Investors in this round

4 investors had bought by the notice of May 24, 2016: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $22 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Whelan · Executive Officer
  • Richard Casey · Executive Officer, Director
  • Annette Bianchi · Director
  • Donald McGovern · Director
  • James Woody · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Bryan Miller, Vice President, Finance. Newest notice filed May 24, 2016. Read the notice at the SEC.

equitySEC
Dec 2011$11 MNo. 2$10 to $50 million

Neuraltus Pharmaceuticals, Inc.: Raise no. 2, Dec 2011

Investors in this round

22 investors had bought by the notice of May 31, 2012: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$11 M of $11 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, other: Series A2 Preferred Stock and Warrants to acquire Series A2 Preferred Stock, including (i) the shares of Series A2 Preferred Stock issuable upon exercise of the Warrants, and (ii) the shares of Common
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Gengos · Executive Officer, Director
  • Annette Bianchi · Director
  • James Woody · Director
  • John Walker · Director
  • Terry Gould · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alan C. Mendelson, Secretary. Newest notice filed May 31, 2012 (1 amendment). Read the notice at the SEC.

equity, optionsSEC
Mar 2009$5 MNo. 1$2 to $10 million

Neuraltus Pharmaceuticals, Inc.: Raise no. 1, Mar 2009

Investors in this round

6 investors had bought by the notice of Apr 7, 2009: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $18 M offered; $13 M still to sell
Smallest investment taken
$200
What was sold
equity, securities to be acquired by exercising them, other: See Footnote to Item No. 13.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$243,490 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in De

People named in the notice

  • Ari Azhir · Executive Officer, Director
  • Annette Bianchi · Director
  • James N. Woody · Director
  • Terry Gould · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Item (b) includes the conversion of a note & interest as of 3/25/09 ($114,054.48) into shares of Series A1 Pref. Stock & warrant exercisable for up to 110,417 shares of Series A1 Pref. Stock, consideration to be received by Issuer upon warrant exercise.”

Signed by Ari Azhir, President and Chief Executive Officer. Newest notice filed Apr 7, 2009. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Neuraltus Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (May 2016).

    SEC Form D · May 2016

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · May 2016

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Neuraltus Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Neuraltus Pharmaceuticals, Inc.
NameRoleNamed in
John WhelanExecutive officerMay 2016
Richard CaseyExecutive officerMay 2016
Andrew GengosExecutive officerMay 2012
Ari AzhirExecutive officerApr 2009
Annette BianchiDirectorMay 2016
Donald McGovernDirectorMay 2016
James WoodyDirectorMay 2016
Richard CaseyDirectorMay 2016
Andrew GengosDirectorMay 2012
John WalkerDirectorMay 2012
Terry GouldDirectorMay 2012
Ari AzhirDirectorApr 2009
James N. WoodyDirectorApr 2009